Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 6:50 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1441–1464 of 3,253 matching trials from the live ClinicalTrials.gov search.

Filters: Not yet recruiting Clear all

Conditions: Aphasia, Malignant Brain Tumor
Interventions: LISTEN (AI-based AAC smartphone app); Device
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 2
States / cities: Boston, Massachusetts

Conditions: Pyruvate Kinase Deficiency, Glucose 6 Phosphate Dehydrogenase Deficiency
Interventions: Vitamin C; Drug
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 3 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Heart Failure, Caregiver
Interventions: HEROIC program, Active Comparator Control 1; Behavioral
Lead sponsor: Johns Hopkins University; Other
Eligibility: 18 Years and older
Enrollment: 500 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2031
U.S. locations: 2
States / cities: Denver, Colorado • Baltimore, Maryland

Conditions: Amyotrophic Lateral Sclerosis, Lou Gehrig's Disease, ALS
Interventions: Not listed
Lead sponsor: Nova Southeastern University; Other
Eligibility: 18 Years to 90 Years
Enrollment: 35 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Fort Lauderdale, Florida

Conditions: Diabetes Mellitus, Type 2
Interventions: Zenagamtide, Semaglutide, Placebo zenagamtide, Placebo semaglutide; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 1,060 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 41
States / cities: La Jolla, California • Lancaster, California • Lincoln, California + 34 more

Conditions: Smoking Cessation
Interventions: LIFT-UP Chatbot; Behavioral
Lead sponsor: University of Utah; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Salt Lake City, Utah

Conditions: Hearing Loss
Interventions: Hearing instrument; Device
Lead sponsor: Sonova AG; Industry
Eligibility: 18 Years to 95 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Aurora, Illinois

Conditions: Congenital Heart Diseases, Cardiac Diseases
Interventions: Not listed
Lead sponsor: Matthias Stuber; Other
Eligibility: Not listed
Enrollment: 300 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 9
States / cities: Los Angeles, California • Atlanta, Georgia • Chicago, Illinois + 6 more

Conditions: Colorectal Cancer, Gastro Esophageal Junctional Cancer, Gastric Cancer (GC), GEJ Adenocarcinoma, PDAC - Pancreatic Ductal Adenocarcinoma, Biliary Tract Cancer (BTC), Gall Bladder Cancer, Cholangiocarcinoma
Interventions: IKS04 antibody drug conjugate ADC + Isumab04 monoclonal antibody; Drug
Lead sponsor: Iksuda Therapeutics Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 4
States / cities: Los Angeles, California • Boston, Massachusetts • Nashville, Tennessee + 1 more

Conditions: B-cell Non Hodgkin Lymphoma
Interventions: 1 X 10^6 cells/kg, 2.5 X 10^6 cells/kg, Dose expansion: The maximum tolerated dose of CAR-T cells; Biological
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years to 80 Years
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Conditions: Frontotemporal Lobar Degeneration (FTLD), Frontotemporal Dementia (FTD), Corticobasal Degeneration, Corticobasal Syndrome (CBS)
Interventions: Not listed
Lead sponsor: BioSensics; Industry
Eligibility: 40 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 2
States / cities: Lutherville, Maryland • Boston, Massachusetts

Conditions: Postsurgical Pain Management, Postsurgical Pain, Chronic, Opioid Use After Surgery
Interventions: TPS-Select, Pharmacologic Pain Management, Interventional Pain Procedures, Psychological Management and Pain Education, Physical Therapy; Device · Drug · Procedure + 1 more
Lead sponsor: University of California, San Francisco; Other
Eligibility: 18 Years and older
Enrollment: 474 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: San Francisco, California

Conditions: Multiple Sclerosis (MS) - Relapsing-remitting, Multiple Sclerosis (MS) Secondary Progressive, Multiple Sclerosis (MS) Primary Progressive
Interventions: Remibrutinib (Open Label); Drug
Lead sponsor: Moein Amin; Other
Eligibility: 18 Years to 60 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: Cleveland, Ohio

Conditions: Lung Non-Squamous Non-Small Cell Carcinoma
Interventions: Biospecimen Collection, Carboplatin, Computed Tomography, Magnetic Resonance Imaging, Pemetrexed, Positron Emission Tomography, Zipalertinib; Procedure · Drug
Lead sponsor: Jonsson Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2030
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: Kidney Transplant Recipient
Interventions: Tacrolimus (Kidney transplant maintenance immunosuppression), Mycophenoate Mofetil, Prednisone (SOC arm), Prednisone (MMF Elimination arm); Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 60 Years and older
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Myocarditis Acute
Interventions: Myocardial contrast echocardiography molecular imaging for inflammation; Diagnostic Test
Lead sponsor: University of Virginia; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Charlottesville, Virginia

Conditions: Amyloid Light-chain Amyloidosis
Interventions: BCMA bispecific; Drug
Lead sponsor: Case Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 64 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 2
States / cities: Rochester, Minnesota • Cleveland, Ohio

Conditions: Pregestational Diabetes, Type 2 Diabetes
Interventions: Exercise; Behavioral
Lead sponsor: Eastern Virginia Medical School; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Norfolk, Virginia

Conditions: Olfactory Dysfunction
Interventions: Clinical and Biomarker Assessments; Other
Lead sponsor: Medical University of South Carolina; Other
Eligibility: 50 Years and older
Enrollment: 500 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2027 – 2032
U.S. locations: 1
States / cities: Charleston, South Carolina

Conditions: Recurrent Glioblastoma, IDH-Wildtype
Interventions: Cerebraca wafer, Temozolomide (for relapsed malignant glioma); Drug
Lead sponsor: Everfront Biotech Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 175 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2027 – 2029
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Microvascular Dysfunction, Microvasculature, Cardiovascular Diseases, Cardiovascular Diseases (CVD), Microvascular Health, Obesity and Overweight
Interventions: Quercetin (dietary supplement), Placebo; Dietary Supplement · Drug
Lead sponsor: Medical College of Wisconsin; Other
Eligibility: 18 Years to 40 Years
Enrollment: 40 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2030
U.S. locations: 1
States / cities: Wauwatosa, Wisconsin

Conditions: Interstitial Lung Disease
Interventions: ⁶⁸Ga-FAPI-46, PET/CT; Drug · Diagnostic Test
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years and older
Enrollment: 10 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Type B Aortic Dissection
Interventions: Auricular Vagus Nerve Stimulator, 3D Printed Earpiece; Device
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years and older
Enrollment: 60 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Physical Activity, Cognition, Aging
Interventions: Exercise, Daylong Movement; Behavioral
Lead sponsor: Wake Forest University; Other
Eligibility: 65 Years and older
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Winstom Salem, North Carolina

Search by objective public record fields.

Listen Aphasia Pilot Study

High-Dose Vitamin C in G6PDA and Pyruvate Kinase Deficiency: A Safety Study

Testing Heart Failure Resilience Intervention for Caregivers (HEROIC) in Advanced Heart Failure

Digital Speech Markers for Monitoring ALS in Spanish Speakers

A Research Study Investigating How Well Zenagamtide at Lower Dose Levels Lowers Blood Sugar and Body Weight Compared to Semaglutide at Lower Dose Levels in People With Type 2 Diabetes Treated With Metformin, Sodium-Glucose Cotransporter 2 Inhibitors (SGLT2i), or Both

LLM Intervention for Tobacco in Underserved Populations (LIFT-UP)

Evaluation of Investigational Hearing Instrument Features

An International Multicenter, Multivendor Evaluation of the Free-Running Framework for Cardiac Function

IKS04 Regimen in Advanced Solid Tumors That Express CA242

Fully Human Bispecific Anti-CD20, Anti-CD19 CAR T Cells for Patients With Relapsed and/or Refractory B Cell Malignancies

A Wearable Sensor Platform for Remote Monitoring of Individuals on the Frontotemporal Dementia Spectrum

An Artificial Intelligence Driven Approach to Optimize Patient Selection for a Transitional Pain Service

A Study of Remibrutinib Using MR Imaging in Relapsing or Progressive MS

Zipalertinib With Carboplatin and Pemetrexed for the Treatment of Resectable, Stage II-IIIB, Non-Small Cell Lung Cancer

Biomarker-Guided Mycophenolate Mofetil Elimination in Low-Risk Older Adult Kidney Transplant Recipients

MCE Molecular Imaging for Myocarditis

Dose Schedule Study of BCMA Bispecific Antibody, Elranatamab, for Newly Diagnosed Immunoglobulin Light Chain (AL) Amyloidosis

Glucose Control in Type 2 Diabetes in Pregnancy

Olfactory Dysfunction in Aging Adults

Comparison of Cerebraca Wafer Plus Temozolomide Versus Temozolomide Alone in Recurrent Glioblastoma

Palmitic Acid and Human Microvascular Function

Study Evaluating 68GA-FAPI-46 PET/CT in Patients With Interstitial Lung Disease

Transcutaneous Auricular Vagus Nerve Stimulation for Attenuation of Inflammatory Response and Blood Pressure in Type B Aortic Dissection

Ecological Momentary Cognitive Assessment